{"filings":[{"id":2357162,"accession_number":"0001493152-26-039247","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2026-08-19T21:00:13+00:00","items":["5.02","8.01"],"status":"ready","headline":"Neuraxis completes stock option exchange; grants RSUs to execs and directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stock Option Exchange effective July 24, 2026: 1,319,394 options cancelled for equivalent RSUs on one-for-one basis.","From exchange: CEO Brian Carrico 199,188 RSUs; CMO Adrian Miranda 199,106; CRO Thomas Carrico 193,678, vesting immediately.","On Aug 13, 2026: new RSU grants to CEO 193,329, CFO Timothy Henrichs 141,479, CMO 133,341, CRO 135,906, vesting over 3 years.","One-time equity awards of 127,120 shares to independent directors on Aug 13, 2026, after comp consultant review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1562596,"accession_number":"0001493152-26-032769","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2026-07-10T11:00:19+00:00","items":["8.01"],"status":"ready","headline":"Neuraxis declares Q2 2026 stock dividend on Series B Preferred, payable in common shares","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Board authorized Q2 2026 stock dividend on Series B Preferred, payable in common stock.","Approximately 80,463 common shares to be issued; price per share $2.38.","Payable July 29, 2026 to holders of record July 21, 2026.","No fractional shares; cash in lieu of fractional shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1029036,"accession_number":"0001493152-26-028489","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2026-06-12T20:50:36+00:00","items":["5.07"],"status":"ready","headline":"Neuraxis stockholders elect all six director nominees, approve equity plan amendments at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Six director nominees elected: Brian Carrico, Dr. Christopher R Brown, Bradley Mitch Watkins, Beth Keyser, Kristen Ferge, Dr. Gilad Aharon; each received 96-99% of votes.","Ratification of Rosenberg Rich Baker Berman as independent auditor for FY 2026 approved (10,187,191 votes for, 0 against, 16,815 abstentions).","Third amendment to Neuraxis 2022 Omnibus Securities and Incentive Plan (solely Section 5.1) approved with 6,730,816 votes for, 727,030 against.","Neuraxis 2025 Employee Stock Purchase Plan approved as amended; Section 5(c) changed to 10% ownership limit from 5%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96791,"accession_number":"0001493152-26-018580","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Neuraxis ups ATM offering to $11.5M after selling 1.125M shares under prior $6.27M program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Apr 21, 2026, Neuraxis filed a prospectus supplement increasing the ATM offering cap to $11,500,000 from $6,270,000.","Between Aug 29, 2025 and Apr 20, 2026, the company sold 1,125,281 common shares under the original ATM agreement.","Sales continue through agent Craig-Hallum Capital Group under the existing effective S-3 registration statement (No. 333-283798).","Proceeds from any future sales will be used for general corporate purposes as determined by management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96790,"accession_number":"0001493152-26-018376","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Neuraxis reports preliminary Q1 2026 net sales of $1.6M, up 77% YoY; operating loss of $1.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents ~$7.1M as of March 31, 2026.","Net sales ~$1.6M for Q1 2026, up 77% from ~$0.9M in Q1 2025.","Gross profit ~$1.4M for Q1 2026.","Operating loss ~$1.7M for Q1 2026.","Preliminary unaudited results; final figures may change materially."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1607883.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127655,"accession_number":"0001493152-25-019186","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Neuraxis gets FDA 510(k) clearance for PENFS to treat functional dyspepsia in ages 8+","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared Neuraxis' PENFS for functional abdominal pain associated with functional dyspepsia and nausea in patients 8 years and older.","This is the first FDA clearance or approval specifically addressing functional dyspepsia in adults.","Clearance based on RCTs and real-world evidence; FDA extrapolated pediatric data to adults.","Company increased ATM offering from $3.3M to $6.27M; no shares sold under prior agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127654,"accession_number":"0001493152-25-019136","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Neuraxis reports preliminary Q3 net sales $0.8M, operating loss $2.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited cash and equivalents of $4.4M as of September 30, 2025.","Q3 net sales approx. $0.8M, gross profit $0.7M, operating loss $2.1M.","Nine-month net sales $2.6M, up from $1.9M in the prior year period.","Preliminary figures subject to change upon completion of quarter-end close."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":2601155.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144434,"accession_number":"0001641172-25-026158","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Neuraxis enters $3.3M ATM offering agreement with Craig-Hallum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM offering of up to $3.3M of common stock at prevailing market prices.","Sales agent Craig-Hallum will receive 3% commission plus up to $50K in legal fees.","Shares sold under effective S-3 registration statement filed Dec 2024.","Agreement allows sales at Company's sole discretion with customary parameters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144433,"accession_number":"0001641172-25-017723","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","1.02","5.02","9.01"],"status":"ready","headline":"Neuraxis ends Masimo partnership on NSS-2 Bridge; pays $200K, forfeits future royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated License and Collaboration Agreement with Masimo Corp., effective July 1, 2025.","Neuraxis to pay Masimo $200,000 in two installments (Dec 2025 and Jun 2026) for trademarks, patents, and inventory.","Neuraxis will no longer receive any licensing payments or revenue from the NSS-2 Bridge device.","Adopted 2025 Employee Stock Purchase Plan, offering 100,000 shares at 15% discount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162790,"accession_number":"0001641172-25-013632","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Neuraxis stockholders approve Series B conversion stock issuance; elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Votes to approve issuance of 20%+ of outstanding common stock upon conversion of Series B Preferred Stock passed with 4.1M for, 129K against, 1.1M broker non-votes.","All six director nominees elected: Brian Carrico, Dr. Christopher R Brown, Bradley Mitch Watkins, Beth Keyser, Kristen Ferge, Dr. Gilad Aharon.","Ratification of auditor Rosenberg Rich Baker Berman, P.A. approved with 5.66M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162789,"accession_number":"0001641172-25-012698","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neuraxis posts investor presentation to website; no specific financial details disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation covering strategy, performance, and objectives posted to ir.neuraxis.com on May 23, 2025.","No financial figures, guidance, or material events were reported in the filing or exhibit.","The 8-K serves solely as a Regulation FD disclosure; full presentation content is not included.","Company remains an emerging growth company; no operational or leadership changes noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162788,"accession_number":"0001641172-25-011973","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Neuraxis announces $5.0M registered direct offering of 1.54M shares at $3.25/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,538,461 shares at $3.25/share; gross proceeds ~$5.0M before fees.","Expected to close on May 22, 2025; net proceeds for working capital and general corporate purposes.","Craig-Hallum Capital Group acting as exclusive placement agent for the offering.","Shares offered under effective shelf registration statement (File No. 333-283798)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162787,"accession_number":"0001641172-25-011939","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Neuraxis settles litigation for $750k payable starting Jan 2026; raises ~$1M from warrant exercises","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settles two lawsuits (Physicians' Litigation and Medical Practice Entities' Litigation) for $750,000 total, payable in 12 equal monthly installments beginning January 2026.","Settlement includes mutual release of all claims among all parties, with no admission of liability.","Received approximately $1M in proceeds from warrant exercises, issuing 430,580 common shares; Series B Preferred converted into 342,016 common shares.","Shares were issued without restrictive legend under the company's effective S-3 registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180757,"accession_number":"0001493152-25-001323","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeurAxis preliminary Q4 revenue up 50% YoY to ~$800K; cash $3.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 revenue ~$800K (+50% YoY); FY2024 revenue ~$2.7M (+11% YoY).","Cash balance as of Dec 31, 2024 was ~$3.7 million.","Insurance coverage expanded to ~45M lives, up from 4M a year ago.","FDA 510(k) clearance for IB-Stim expanded to ages 8-21; new CPT code for PENFS.","Commercialization of FDA-approved Rectal Expulsion Device (RED) begins Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":2685925.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197600,"accession_number":"0001493152-24-047623","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Neuraxis appoints Dr. Gil Aharon to board effective Jan 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gil Aharon appointed to Neuraxis board effective Jan 1, 2025, as designee of investors in recent $5M Series B financing.","Dr. Aharon co-founded Rosalind Advisors and purchased $250,000 of Series B Convertible Preferred Stock in the transaction.","He has not yet been assigned to any board committee; director compensation is undetermined.","No family relationships with other directors or officers; no other material interests in related-party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197599,"accession_number":"0001493152-24-047196","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Neuraxis amends Series B Preferred terms: extends dividends, increases authorized shares, revises voting rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased authorized Series B Preferred shares from 4,000,000 to 5,000,000.","Extended 8.5% annual dividend right by 18 months, now through December 31, 2026.","Amended voting rights: each Series B share votes equal to common shares convertible at $3.80 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197598,"accession_number":"0001493152-24-046285","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Neuraxis raises ~$5M through Series B Convertible Preferred Stock to three investors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 2,100,840 shares of Series B Preferred Stock at $2.38 stated value for aggregate $5M, closed Nov 13, 2024.","Preferred ranks senior to common, convertible at any time into common shares; proceeds for working capital.","Registration rights require filing resale statement within 30 days; 1% monthly late penalty up to 6% of subscription amount, plus 18% interest if unpaid.","Investor board nominee Gil Aharon to join Board effective Jan 1, 2025, as long as investor holds ≥5% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197597,"accession_number":"0001493152-24-044545","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeurAxis Q3 revenue up 40% to $667K; operating loss narrows 45%; secures $5M investment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $667K, +40% YoY; unit sales +50%.","Operating loss $1.7M, improved 45% from $3.0M; net loss $1.8M, improved 80%.","Expanded insurance coverage to ~35M lives (from 4.5M); new FDA clearance for IB-Stim ages 8-21.","Received CPT Category I code for PENFS effective Jan 1, 2026.","Entered $5.0M investment agreement (closing mid-Nov), replacing prior $3.2M commitment; cash on hand $261K."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1924760.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197596,"accession_number":"0001493152-24-041597","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Neuraxis cuts Flagstaff investment to $1.8M, raises $145k from new Series B preferred sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fourth Amendment reduces Flagstaff SPA total from $5M to $1.8M; $800k received, $1M due by Dec 31, 2024.","New SPAs with multiple investors for 60,924 Series B Preferred shares at $2.38/share, aggregate $145k.","Series B Preferred convertible into common at any time; dividend/liquidation rights expire June 30, 2025.","Proceeds from the new SPAs to be used for working capital and general corporate purposes.","Flagstaff SPA termination terms revised; automatic upon full payment or breach with cure through Jan 9, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213823,"accession_number":"0001493152-24-036212","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Neuraxis converts $4.94M of convertible notes into 2.07M Series B Preferred shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["$4,935,001.90 of Preferred Stock Notes automatically converted into 2,073,524 Series B Preferred shares at $2.38/share.","Conversion occurred on Sept 9, 2024 after stockholder approval on Aug 15, 2024 and filing of Certificate of Designation.","Shares issued to Flagstaff International and other accredited investors; exempt from registration under Section 4(a)(2).","Series B Preferred ranks senior to common stock on liquidation, convertible into common at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213822,"accession_number":"0001493152-24-033444","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Neuraxis shareholders approve expanded equity plan and blank check preferred","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with 85%–99.99% votes for; quorum of 65.61% achieved.","Incentive plan amended to double share pool to 600K plus 5% annual evergreen through 2031.","Blank check preferred stock authorized (3.52M votes for).","Issuance of 20%+ of common on conversion of Series B preferred or notes approved (3.63M for).","Non-binding say-on-pay approved; frequency set at once every three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213821,"accession_number":"0001493152-24-030873","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeurAxis Q2 revenue down 5.3% to $611.5K; net loss widens to $2.9M; insurance coverage expands to 22.5M lives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $611.5K, down 5.3% YoY; gross margin 88.0% vs 89.5%.","Net loss $2.9M, up 30.5% YoY; operating loss $2.2M, up 97.5%.","Covered lives grew to 22.5M from 4.5M a year ago; commitment from payer with 12M lives starting Oct 1.","Submitted RED device to FDA for clearance expected Q4 2024; submitted label expansion to ages 8-21.","Secured additional $3.0M funding in May; total committed financing $9.1M; cash $1.8M, short-term debt $4.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":1258135.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213820,"accession_number":"0001493152-24-026362","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NeurAxis grants fully vested stock to three non-employee directors; initiates quarterly equity compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three non-employee directors (Ferge, Keyser, Watkins) granted fully vested shares for services through March 31, 2024.","Shares valued at $2.78 per share (closing price June 28, 2024); first issuance under 2022 Plan post-IPO.","Future quarterly grants: each director to receive $12,500 in stock per quarter, totaling $50,000 annual equity compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233042,"accession_number":"0001493152-24-021615","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Neuraxis raises $3M via convertible notes at 8.5% interest; warrants amended","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued ~$3M aggregate principal convertible notes to three institutional investors; 8.5% annual interest payable quarterly.","Notes mature June 21, 2025; convert into Series B Preferred at $2.38/share after stockholder approval and certificate filing.","Proceeds for working capital and corporate purposes; no dividends or payments to affiliates permitted.","Holders of >70% of outstanding 2023 warrants agreed to waive anti-dilution rights in connection with the note issuance.","Stockholder approval for Series B Preferred authorization not yet obtained; conversion delayed until approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233041,"accession_number":"0001493152-24-014829","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Neuraxis COO Dan Clarence terminated; severance through Oct 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Dan Clarence employment terminated effective April 10, 2024.","Severance: salary continuation at $275,000/yr through Oct 10, 2024.","Company will also pay Mr. Clarence's COBRA premiums through Oct 10, 2025.","No replacement named; CEO Brian Carrico remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233040,"accession_number":"0001493152-24-014075","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"NeurAxis reports FY2023 net loss $14.6M; restates Q3 2023 due to $3.7M accounting error","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2023 revenue $2.5M down 8.4% YoY; net loss widened to $14.6M from $4.8M in 2022.","Restating Q3 2023 financials: $3.7M understatement of net loss and APIC due to warrant liability misclassification.","Cash at Dec 31, 2023 only $78.6K; secured $6.1M in convertible notes ($1.5M funded by Mar 31, 2024).","Insured lives expanded to ~16M (up 300% YoY), targeting 50M by end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251204,"accession_number":"0001493152-24-011761","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Neuraxis increases Flagstaff financing to $5M, replaces preferred with convertible note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment raises Flagstaff investment from $3M to $5M via convertible promissory note.","Note carries 8.5% interest, matures in 15 months, convertible into Series B Preferred at $2.38/share.","Company has received $400,000 to date; 13 additional monthly installments scheduled through March 2025.","Conversion contingent on stockholder approval of Series B Preferred authorization, targeted by Sept 30, 2024.","Proceeds restricted to working capital and general corporate purposes; no dividends or affiliate payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251203,"accession_number":"0001493152-24-009493","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeurAxis appoints Kristin Ferge to Board as Audit Committee Chair","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Kristin Ferge, 50, appointed to Board effective March 7, 2024, until next annual meeting.","Appointed Chairman of Audit Committee; designated independent and audit committee financial expert.","Annual compensation of $60,000 cash plus common stock valued at $50,000.","Ferge is President/CFO of Capri Communities and former EVP, Treasurer, and CAO of Brookdale Senior Living.","Company also furnished investor presentation under Item 7.01 (contents not provided)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251202,"accession_number":"0001493152-24-006888","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Neuraxis raises $457k via convertible notes; amends Flagstaff $3M SPA","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered SPAs with two accredited investors on Feb 9 & 14 for $457k aggregate; notes bear 8.5% interest, convertible to Series B Preferred at $2.38/share.","Amended Nov 2023 SPA with Flagstaff International on Feb 12; Flagstaff will now receive convertible notes for $200k monthly installments until stockholder approval."," electrodes: Alexander Capital LP received 10% cash fee; net proceeds ~$400k for working capital and general corporate purposes.","Stockholder approval for Series B Preferred authorization has not yet been sought; conversion of all notes is contingent on that approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251201,"accession_number":"0001493152-24-004424","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeurAxis appoints Timothy Henrichs as CFO; John Seale resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Henrichs appointed CFO effective Feb 5, 2024, replacing John Seale who resigned Jan 30.","Henrichs receives $330,000 base salary plus 100,000 shares of common stock as inducement.","Henrichs resigned from the board as independent director effective Feb 2, 2024.","Henrichs previously served as CFO of Renovo Home Partners and EVP/CFO of Follett Corporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268776,"accession_number":"0001493152-23-045436","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Neuraxis lowers warrant exercise price to $2.38; SPA not yet closed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercise price of all warrants reduced from $5.25 to $2.38 per share due to SPA with Flagstaff International.","SPA for Series B Preferred Stock at $2.38/share has not been paid or issued as of Dec 19, 2023.","New 2023 warrants for 609,760 shares and PA warrants for 144,990 shares not yet issued.","2022 warrant share count unchanged (793,655 shares); total warrants ~1.42M shares at new lower price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268775,"accession_number":"0001493152-23-040826","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Neuraxis secures $3M financing via Series B preferred stock at $2.38/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate purchase price $3,000,000; paid in 15 monthly installments of $200,000 each.","Transaction subject to stockholder approval of Series B Preferred Stock amendment.","Series B convertible into common stock; ranks senior to common on liquidation.","Funds to support sales/marketing for IB-Stim™ and launch of RED device in 2024.","Investor is Flagstaff International, an affiliate of Inspire Health Alliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285885,"accession_number":"0001493152-23-033281","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Neuraxis Q2 2023 revenue down 5% to $646K; net loss widens to $2.24M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $646K, -5% YoY from $683K; gross margin improved to 89.5% from 88.4%.","Net loss $2.236M ($1.21/share) vs $1.517M ($0.87/share) in Q2 2022.","IPO completed, net proceeds ~$6.1M; now trading on NYSE American under NRXS.","R&D spend surged to $110K from $14K YoY; G&A rose to $1.51M from $1.13M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285884,"accession_number":"0001493152-23-029326","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2023-08-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeurAxis reports over $8M in cumulative IB-Stim revenue through March 31, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over $8M in revenue from IB-Stim since commercial launch after FDA clearance for pediatric functional abdominal pain and IBS.","Approximately $2M of total revenue was generated in 2019 and 2020.","Company is conducting clinical trials for four additional pediatric indications: chronic nausea, post-concussion syndrome, chemo-induced nausea, and cyclic vomiting.","CEO Brian Carrico cites growing adoption, non-drug therapy trend, and recently completed IPO funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285883,"accession_number":"0001493152-23-027328","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Neuraxis prices IPO of 1,098,667 shares at $6.00, raising ~$6.6M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 1,098,667 shares at $6.00 per share; gross proceeds expected ~$6,592,000.","Shares begin trading Aug 9, 2023 on NYSE American under symbol NRXS; closing expected Aug 11.","Underwriters have 45-day option to purchase up to 164,800 additional shares at the offering price.","Net proceeds to fund sales/marketing, R&D, payments to executives per employment agreements, and general corporate.","Alexander Capital L.P. is sole book-running manager for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}